Antibiotics markets are huge and the need for new classes of antibiotics is great, but the risks give investors pause.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A new antibiotic with potent activity targets MscL
The Journal of Antibiotics Open Access 04 February 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout

References
Anonymous. Nat. Rev. Drug Discovery 5, 446–447 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Christoffersen, R. Antibiotics—an investment worth making?. Nat Biotechnol 24, 1512–1514 (2006). https://doi.org/10.1038/nbt1206-1512
Issue Date:
DOI: https://doi.org/10.1038/nbt1206-1512
This article is cited by
-
A new antibiotic with potent activity targets MscL
The Journal of Antibiotics (2015)
-
Importance of microbial natural products and the need to revitalize their discovery
Journal of Industrial Microbiology and Biotechnology (2014)
-
Potent in vitro synergism of fusidic acid (FA) and berberine chloride (BBR) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA)
World Journal of Microbiology and Biotechnology (2014)
-
Antimicrobials, drug discovery, and genome mining
Applied Microbiology and Biotechnology (2013)